PRIMAGE

Medical imaging
Artificial intelligence
Childhood cancer research

D1.1 – Users' requirements and use scenarios

Project Full Title: *PRedictive In-silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis, Empowered by imaging biomarkers Business Place*
Project acronym: *PRIMAGE*
Project type: Horizon 2020 | RIA (Topic SC1-DTH-07-2018)
Grant agreement no: 826494

[redacted]

[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]
[redacted]	[redacted]

[redacted]

[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]

Introduction

As part of WP1, Deliverable 1.1 is strongly linked to the first objective of the PRIMAGE Project with the aim to design a Decision Support System (DSS) for cancer management with advanced functionality and usability guided by the clinical partners (European Key Opinion Leaders in Paediatric Oncology) located in the three respective project partner institutions named CCRI, HULAFE and UKOELN, which all are leading European clinical centres in Paediatric Oncology. The goal is to support clinical practitioners in their daily clinical practice. Therefore, in a first step the project aims to truly understand the needs of users, aligned with their current workflows. The present deliverable summarizes the work of the clinical partners on the Clinical Scenarios, the Clinical End Points (CEPs) and the User Needs and Requirements for Neuroblastoma (NB) and Diffuse Intrinsic Pontine Glioma (DIPG), the two rare children tumour diseases addressed in PRIMAGE project. In accordance with the developing partners this description of clinical requirements and platform features and user requirements will be addressed by PRIMAGE platform.

Following this deliverable, the definition of data requirements, e-forms, quality procedures and authorizations will be reported in Deliverable 3.1.

[redacted]

[redacted]

[redacted]

[redacted]

[redacted]

[redacted]

[redacted]

- [redacted]
- [redacted]
- [redacted]
- [redacted]

[redacted]

[redacted]

[redacted]

- [redacted]
- [redacted]
- [redacted]
- [redacted]
- [redacted]
- [redacted]

3. CONCLUSION

The present Deliverable 1.1 analyzes the users' requirements and use scenarios that need to be fulfilled by the PRIMAGE platform based on the two solid tumour diseases (NB and DIPG).

NB and DIPG were chosen for platform validation and the clinical scenarios and CEPs are based on disease treatments and clinical trials. In consultation with all clinical partners involved it was possible to generate crucial clinical scenarios and CEPs for an optimized platform construction and diagnostic method based on the initial imaging of diagnosis.

"Users' needs and requirements" is a very important aspect with regard to the goal of the project, because the end-user is the one who finally has to deal with the platform. The goal of the project is to provide an optimized diagnostic method based on the initial imaging of diagnosis. PRIMAGE should support the daily clinical practice of clinicians or attending physicians. Towards this, it should be aligned with their current workflows and as user-friendly as possible.

Important content that must be addressed in related deliverables, D2.2 and D3.1, affect the platform architecture design and interconnectivity aspects as well as data requirements, e-forms and data quality. As agreed between clinical and technical partners, the present description of clinical and users' requirements will be addressed by PRIMAGE platform.